Sorilux Aerosol, Foam
Product Images NDC 51862-376

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sorilux (NDC 51862-376). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mayne Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Sorilux 01)

FDA Label Image

Figure A (Sorilux 02)

FDA Label Image

Figure B (Sorilux 03)

FDA Label Image

Figure C (Sorilux 04)

FDA Label Image

Figure D (Sorilux 05)

FDA Label Image

Figure E (Sorilux 06)

FDA Label Image

Figure F (Sorilux 07)

FDA Label Image

Figure G (Sorilux 08)

FDA Label Image

Principal Display Panel (60 gram Can Carton)

Principal Display Panel (60 gram Can Carton)
Each can of Sorilux Foam contains 60 grams of a medication called calcipotriene. It is intended for topical use only, and should not be applied to the eyes or used orally or intravaginally. Dosage and prescribing information should be obtained from a patient's physician. The can must be shaken prior to use, and users should avoid puncturing or incinerating the container. The foam is flammable, and users should avoid smoking or exposing it to fire or flame. The product should be kept out of reach of children, and should not be stored above 49°C or in direct sunlight. It contains several ingredients, including calcipotriene, cetyl alcohol, and dibasic sodium phosphate. Adverse reactions should be reported to Mayne Pharma or the FDA.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.